These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 20452419)

  • 1. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis.
    Kliment CR; Oury TD
    Free Radic Biol Med; 2010 Sep; 49(5):707-17. PubMed ID: 20452419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review.
    Fois AG; Paliogiannis P; Sotgia S; Mangoni AA; Zinellu E; Pirina P; Carru C; Zinellu A
    Respir Res; 2018 Mar; 19(1):51. PubMed ID: 29587761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.
    Hewlett JC; Kropski JA; Blackwell TS
    Matrix Biol; 2018 Oct; 71-72():112-127. PubMed ID: 29625182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis.
    Hosseinzadeh A; Javad-Moosavi SA; Reiter RJ; Yarahmadi R; Ghaznavi H; Mehrzadi S
    Expert Opin Ther Targets; 2018 Dec; 22(12):1049-1061. PubMed ID: 30445883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2.
    Walters DM; Cho HY; Kleeberger SR
    Antioxid Redox Signal; 2008 Feb; 10(2):321-32. PubMed ID: 17999635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitigation of Oxidative Stress in Idiopathic Pulmonary Fibrosis Through Exosome-Mediated Therapies.
    Wang Z; Zhang Y; Li X
    Int J Nanomedicine; 2024; 19():6161-6176. PubMed ID: 38911503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disturbed redox-balance in pulmonary fibrosis is modulated by the plant flavonoid quercetin.
    Veith C; Drent M; Bast A; van Schooten FJ; Boots AW
    Toxicol Appl Pharmacol; 2017 Dec; 336():40-48. PubMed ID: 28987380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.
    Craig VJ; Zhang L; Hagood JS; Owen CA
    Am J Respir Cell Mol Biol; 2015 Nov; 53(5):585-600. PubMed ID: 26121236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis.
    Cameli P; Carleo A; Bergantini L; Landi C; Prasse A; Bargagli E
    Inflammation; 2020 Feb; 43(1):1-7. PubMed ID: 31297749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective Effects of Extracellular Matrix-Derived Hydrogels in Idiopathic Pulmonary Fibrosis.
    Evangelista-Leite D; Carreira ACO; Gilpin SE; Miglino MA
    Tissue Eng Part B Rev; 2022 Jun; 28(3):517-530. PubMed ID: 33899554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions.
    Xu X; Dai H; Wang C
    Clin Respir J; 2016 Mar; 10(2):133-41. PubMed ID: 25047066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis.
    Ding Q; Luckhardt T; Hecker L; Zhou Y; Liu G; Antony VB; deAndrade J; Thannickal VJ
    Drugs; 2011 May; 71(8):981-1001. PubMed ID: 21668038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and immunity in IPF pathogenesis and treatment.
    Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M
    Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs.
    Hadjicharalambous MR; Lindsay MA
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy.
    Varone F; Gibiino G; Gasbarrini A; Richeldi L
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6379-6386. PubMed ID: 31364146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deglycosylated Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1 Signaling Pathway.
    Ruan H; Gao S; Li S; Luan J; Jiang Q; Li X; Yin H; Zhou H; Yang C
    Molecules; 2021 May; 26(9):. PubMed ID: 34068694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis.
    Ptasinski VA; Stegmayr J; Belvisi MG; Wagner DE; Murray LA
    Am J Respir Cell Mol Biol; 2021 Oct; 65(4):347-365. PubMed ID: 34129811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis.
    Nishioka Y; Azuma M; Kishi M; Aono Y
    J Med Invest; 2013; 60(3-4):175-83. PubMed ID: 24190033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis.
    Phan THG; Paliogiannis P; Nasrallah GK; Giordo R; Eid AH; Fois AG; Zinellu A; Mangoni AA; Pintus G
    Cell Mol Life Sci; 2021 Mar; 78(5):2031-2057. PubMed ID: 33201251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Tale of Two Proteolytic Machines: Matrix Metalloproteinases and the Ubiquitin-Proteasome System in Pulmonary Fibrosis.
    Roque W; Boni A; Martinez-Manzano J; Romero F
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.